Enterprise Value to EBITDA Ratio: Protara Therapeutics (TARA)
A critical factor for Protara Therapeutics (TARA) is the outcome of bladder tumor therapy trials and FDA approval, which is reflected in the market price action at 0.00. The business focuses on developing drugs for lymphatic pathologies and rare oncological diseases, positioning itself for potential monopoly status. Protara Therapeutics (TARA) is currently in the R&D stage, where high development costs temporarily outweigh profits.
Financial and market metric breakdowns for protaratx.com (TARA)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity Protara Therapeutics|TARA - Long-Term Liabilities to Equity|Short-Term Debt to Equity Protara Therapeutics, Inc.|TARA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Protara Tx|TARA - Long-Term Debt|Company Current Liabilities Protara Therapeutics|Quick Ratio protaratx.com
- business earnings and investment ratios data:
TARA - Net Profit|Expected Profit Protara Therapeutics|TARA - Company Value to Net Income|Forward P/E Multiple Protara Therapeutics|TARA - PEG Multiple|Enterprise Value to EBITDA Ratio Protara Tx|TARA - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Protara Therapeutics|TARA - Earnings per share for the last four quarters|Quarterly EPS earnings growth protaratx.com|TARA - Earnings per share increase in current year|Earnings growth forecast for next year Protara Therapeutics
Summary company analysis:TARA (Protara)
This metric compares the total enterprise value of a business with its operating income, neutralizing the impact of taxes and debt load. This multiple determines the payback period of assets, allowing an investor to assess the fundamental value of the issuer. For Protara Therapeutics (TARA), with its costly clinical trials, the company's EV/EBITDA ratio reflects the balance between capital expenditures and the scaling potential of the therapy. The current value of 0.00 serves as an indicator of the market valuation of the business's credit resilience.
Competitor analysis
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|DCTH: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Y-mAbs Therapeutics, Inc. YMAB|Business Value to Operating Income Before Depreciation AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Accuray, Inc.|SLS (sellaslifesciences.com) - Enterprise Value to EBITDA Ratio|ACTU: Enterprise Value to Operating Income Before Depreciation Ratio|CTOR (Citius Oncology) - EV/EBITDA Multiple|EV/EBITDA Multiple TuHURA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Fate Therapeutics Corp (FATE)|WHWK (aadibio.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TCRX (TScan Therapeutics, Inc.)|EV/EBITDA Multiple Champions Oncology Inc CSBR|XBIT: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CVM (CEL-SCI Corporation)|OSTX (OS Therapies Inc) - Enterprise Value to EBITDA Ratio|RADX: Enterprise Value to Operating Income Before Depreciation Ratio|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|ANL: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xilio Therapeutics XLO|Business Value to Operating Income Before Depreciation RENB|Mural Bio - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|onkuretherapeutics.com (OKUR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Limited)|CRIS (Curis Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Apollomics Corp APLM|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|EV/EBITDA Multiple advanbiomed.com (ADVB)|Genprex - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio CLDI (Calidi Biotherapeutics Inc.)|Sunshine Biopharma - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Xenetic Biosciences XBIO|SLRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio purple-biotech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Oncology Network Inc|BeiGene Ltd. (BGNE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CKPT (Checkpoint Therapeutics, Inc)|Enterprise Value to Operating Income Before Depreciation Ratio ELEV|EV/EBITDA Multiple ICAD (iCAD)|EV/EBITDA Multiple Ikena Oncology Inc. IKNA|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics)|MOR: EV/EBITDA Multiple|NAYA Biosciences Corp (NAYA) - EV/EBITDA Multiple|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
